Summary
The regulation of hormonal influences on mammary tumor development and growth resides in the hypothalamus. The two major hormones essential for mammary tumor development in the rat and mouse, and also for mammary tumor growth in the rat, are prolactin and estrogen. Prolactin secretion is directly controlled by the hypothalamus, and estrogen indirectly via the pituitary gonadotropins. Treatments that increase prolactin secretion in the rat and mouse increase the incidence of spontaneous mammary tumors, whereas treatments that decrease prolactin or estrogen secretion decrease the incidence of spontaneous mammary tumors in these species. In carcinogen treated rats, either an increase or decrease in prolactin or ovarian hormones inhibits development of mammary cancers.
After the appearance of mammary tumors in rats, spontaneous or carcinogen-induced, a reduction in prolactin results in reduced mammary tumor growth, and an increase in prolactin in enhanced mammary tumor growth. Either a reduction in estrogen or an excess of estrogen inhibits mammary tumor growth in rats. Large doses of estrogen inhibit mammary tumor growth by preventing prolactin from stimulating tumor growth. In mice with well established mammary tumors, prolactin or estrogen have relatively little effect since these tumors are largely autonomous.
In women there is inconclusive evidence as yet that prolactin plays a role in breast cancer development and growth. Women with breast cancer have normal serum prolactin levels. Regression of breast cancer after hypophysectomy may be due in part to loss of prolactin, but perhaps to loss of other pituitary hormones as well. Ovariectomy or early pregnancy have been shown to be associated with a reduced incidence of breast cancer, and either ovariectomy or treatment with high doses of estrogen can induce regression of existing breast cancer in some patients. In view of the importance of prolactin and estrogen in development and growth of mammary tumors, and in view of their direct or indirect control by the hypothalamus, it is possible that some mammary tumors have their origin in the hypothalamus.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Armstrong, B., Stevens, N., Doll, R.: Retrospective study of the association between use of rauwolfia derivatives and breast cancer in English women. Lancet2, 672–675 (1974).
Boyns, A. R., Cole, E. N., Griffiths, K., Roberts, M. M., Buchan, R., Wilson, R. G., Forrest, A. P. M.: Plasma prolactin in breast cancer. Europ. J. Cancer9, 99–102 (1973).
Chen, H. J., Bradley, C. J., Mettes, J.: Stimulation of growth of carcinogeninduced mammary cancers in rats by thyrotropin-releasing hormone. Cancer Res.37, 64–66 (1977).
DeSombre, E. R., Kledzik, G., Marshall, S., Meites, J.: Estrogen and prolactin receptor concentrations in rat mammary tumors and response to endocrine ablation. Cancer Res.36, 354–358 (1976).
Franks, S., Ralphs, D. N. L., Seagrott, V., Jacobs, H. S.: Prolactin concentrations in patients with breast cancer. Brit. Med. J.4, 320–321 (1974).
Friesen, H., Hwang, P., Guyda, H., Tolis, G., Tyson, J., Myers, R. A.: Radioimmunoassay for human prolactin. In: Prolactin and Carcinogenesis (Boyns, A. R., Griffiths, K., eds.), pp. 64–80. Cardiff: Alpha Omega Alpha Pub. 1972.
Hayward, J.: Hormones and Human Breast Cancer. Berlin-Heidelberg-New York: Springer. 1970.
Heinonen, O. P., Shapiro, S., Tuominen, L., Turunen, M. I.: Reserpine use in relation to breast cancer. Lancet2, 675–677 (1974).
Holdaway, I. M., Friesen, H. G.: Hormone binding by human mammary carcinoma. Cancer Res.37, 1946–1952 (1977).
Keirtz, H., Jesdinsky, H. J., Schröter, P. M., Lindtner, E.: Reserpine and breast cancer in women in Germany. Europ. J. Clin. Pharmacol.11, 79–83 (1977).
Kelly, P. A., Bradley, C., Shiu, R. P. C., Meites, J., Friesen, H. G.: Prolactin binding to rat mammary tumor tissue. Proc. Soc. Exp. Biol. Med.146, 816–819 (1974).
Kledzik, G. S., Bradley, C. J., Meites, J.: Reduction of carcinogen-induced mammary cancer incidence in rats by early treatment with hormones or drugs. Cancer Res.34, 2953–2956 (1974).
Kledzik, G. G., Bradley, C. J., Marsball, S., Campbell, G. A., Meites, J.: Effects of high doses of estrogen on prolactin-binding activity and growth of carcinogen-induced mammary cancers in rats. Cancer Res.36, 3265–3268 (1976).
Mack, T. M., Henderson, B. E., Gerkins, V. R., Arthur, M., Baptista, J., Pike, M. C.: Reserpine and breast cancer in a retirement community. New Eng. J. Med.292, 1366–1371 (1975).
Mac Mahon, B., Cole, P., Brown, J.: Etiology of human breast cancer: A review. J. Nat. Cancer Inst.50, 21–42 (1973).
Meites, J.: Relation of prolactin and estrogen to mammary tumorigenesis in the rat. J. Nat. Cancer Inst.48, 1217–1224 (1972 a).
Meites, J.: Relation of prolactin to mammary tumorigenesis and growth in rats. In: Prolactin and Carcinogenesis (Boyns, A. R., Griffiths, K., eds.), pp. 54–63. Cardiff: Alpha Omega Alpha Pub. 1972 b.
Meites, J., Cassell, E., Clark, J.: Estrogen inhibition of mammary tumor growth in rats; counteraction by prolactin. Proc. Soc. Exp. Biol. Med.137, 1225–1227 (1971).
Meites, J., Lu, K. H., Wuttke, W., Welsch, C. W., Nagasawa, H., Quadri, S. K.: Recent studies on functions and control of prolactin secretion in rats. Recent Prog. Horm. Res.28, 471–516 (1972).
Meites, J., Simpkins, J., Bruni, J., Advis, J.: Role of biogenic amines in control of anterior pituitary hormones. IRCS J. Med. Sci.5, 1–7 (1977).
Meites, J., Huang, H. H., Riegle, G. D.: Relation of the hypothalamo-pituitary-gonadal system to decline of reproductive functions in aging female rats. In: Hypothalamus and Endocrine Functions (Labrie, F., Meites, J., Pelletier, G., eds.), pp. 3–20. New York: Plenum Pub. 1976.
Minton, J. P.: Prolactin and human breast cancer. Am. J. Surg.128, 628 to 630 (1974).
Or, H. W.: Oral contraceptive use and breast diseases. In: Pharmacology of Steroid Contraceptive Drugs (Garattini, S., Berendes, H. W., eds.), pp. 179–184. New York: Raven Press. 1977.
Pass, K. A., Meites, J.: Enhanced growth of carcinogen-induced mammary tumors in rats by sulpiride. IRCS J. Med. Sci.5, 241 (1977).
Pearson, O. H., Llerena, O., Llerena, L., Molina, A., Butler, T.: Prolactindependent rat mammary cancer: a model for man? Trans. Assoc. Am. Physicians82, 225–238 (1969).
Quadri, S. K., Clark, J. L., Meites, J.: Effects of LSD, pargyline and haloperidol on mammary tumor growth in rats. Proc. Soc. Exp. Biol. Med.142, 22–26 (1973).
Quadri, S. K.: Effects of central acting drugs and ergot derivatives on prolactin and GH secretion, on growth of pituitary and mammary tumors, and on reproduction in old rats. Ph.D. Thesis, Mich. State Univ., 1973.
Stoll, B. A.: Brain catecholamines and breast cancer. A hypothesis. Lancet1, 431–432 (1972).
Talwalker, P. K., Mettes, J., Mizuno, H.: Mammary tumor induction by estrogen or anterior pituitary hormones in ovariectomized rats given7, 12-dimethyl-1, 2-benzanthracene. Proc. Soc. Exp. Biol. Med.116, 531–534 (1964).
Welsch, C. W., Nagasawa, H.: Prolactin and murine mammary tumorigenesis: A review. Cancer Res.37, 951–963 (1977).
Welsch, C. W., Clemens, J. A., Meites, J.: Effects of hypothalamic and amygdaloid lesions on development and growth of carcinogen-induced mammary tumors in the female rat. Cancer Res.29, 1541–1549 (1969).
Welsch, C. W., Clemens, J. A., Meites, J.: Effects of multiple pituitary homografts or progesterone on7, 12-dimethylbenz(a)anthracene-induced mammary tumors in rats. J. Nat. Cancer Inst.41, 465–471 (1968).
Welsch, C. W., Lambrecht, L. K., Hassett, C. C.: Suppression of mammary tumorigenesis in C3H/He mice by ovariectomy or treatment with 2-bromo-α-ergocryptine: a comparison. J. Nat. Cancer Inst.58, 1135 to 1138 (1977).
Welsch, C. W., de Iturri, C., Brennan, M. J.: DNA synthesis of human, mouse and rat mammary carcinomasin vitro: Influence of insulin and prolactin. Cancer Res.38, 1272–1281 (1976).
Author information
Authors and Affiliations
Additional information
Aided in part by research grant CA10771 from the National Cancer Institute, United States Public Health Service.
Rights and permissions
About this article
Cite this article
Meites, J. Relation of the neuroendocrine system to the development and growth of experimental mammary tumors. J. Neural Transmission 48, 25–42 (1980). https://doi.org/10.1007/BF01670031
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01670031